SCHIELD Biodegradable Implant MPT

• User: Female
• Hormonal: Hormonal
• Delivery type:
  • Subdermal
• Intended Duration:
  • Long-Acting
• Development Stage: Pre-Clinical
• Developer(s)/researcher(s): RTI International

Details

• API: Islatravir, Progestin (Non-Specific)
• Target: Progesterone Receptor
• Mechanism of Action:
  • Ovulation Inhibition
  • Cervical Mucus Changes
  • Endometrial Changes
• Inactive Materials: Polycaprolactone, GRAS excipient
• Regimen: 1 Insertion/1-2 Years
• MPT: Potential MPT
• Promising Attributes: BDIs provide a long duration of contraceptive efficacy, removability for the majority of the period of use, and no need to return to a medical provider for removal. The addition of an HIV preventative option broadens the appeal of the method.

Product Status

History

Publications